Company Filing History:
2 out of 9 
1 out of 24 
1 out of 7 Years Active: 2018-2022
Title: Oliver Krämer: Innovator in Pharmaceutical Chemistry
Introduction
Oliver Krämer is a notable inventor based in Nackenheim, Germany. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of targeted therapies for various diseases. With a total of two patents to his name, Krämer's work focuses on innovative compounds that have the potential to improve treatment outcomes for patients.
Latest Patents
Krämer's latest patents include groundbreaking research on FLT3 inhibitors. The first patent, titled "Synthesis, pharmacology and use of new and selective FMS-like tyrosine kinase 3 (FLT3) inhibitors," relates to small molecule compounds designed to treat acute myeloid leukemia (AML). This invention outlines methods for synthesizing these compounds and their application in medical treatments. The second patent, "HDAC6 inhibitors and their uses," focuses on small molecule compounds that act as HDAC inhibitors, offering potential treatments for various cancers. This patent also details methods for synthesizing these compounds and their therapeutic applications.
Career Highlights
Throughout his career, Oliver Krämer has worked with prestigious institutions such as the University of Regensburg and Friedrich Schiller University Jena. His research has been instrumental in advancing the understanding of targeted cancer therapies and their mechanisms of action. Krämer's dedication to innovation in pharmaceutical chemistry has positioned him as a key figure in the field.
Collaborations
Krämer has collaborated with several professionals in his field, including Siavosh Mahboobi and Andreas Sellmer. These collaborations have fostered a productive environment for research and development, leading to significant advancements in the treatment of diseases.
Conclusion
Oliver Krämer's contributions to pharmaceutical chemistry through his innovative patents highlight his commitment to improving patient care. His work continues to influence the development of targeted therapies, making a lasting impact in the medical field.